Interventional cardiologist Dr. Alan Zajarias performed the first U.S. procedure using the device in St. Louis. The clinical debut serves as the starting point for a controlled rollout, with the company prioritizing elite cardiovascular centers to ensure precise execution and procedural support during the initial phase. According to Dr. Zajarias, the catheter demonstrated stability and efficient inflation and deflation times, qualities deemed essential for navigating complex anatomical environments during valvuloplasty.
In section Releases
Corvention Begins U.S. Rollout of KardiaPSI Catheter
Flagstaff-based medical device firm Corvention has initiated the limited commercial launch of its KardiaPSI balloon catheter in the United States. The milestone follows the platform's recent FDA 510(k) clearance, marking a shift toward broader clinical adoption for the structural heart technology after its successful domestic debut in Missouri.
CEO Michael Franklin noted that the launch is designed to provide clinicians with specialized tools intended to optimize patient outcomes. Founded in 2021, Corvention is now managing the transition from development to commercialization, encouraging cardiovascular centers interested in the technology to coordinate directly with their clinical affairs team regarding site readiness and scheduling.
Comments (0)
No comments yet. Be the first!